References 1 Schipf A, Mayr D, Kirchner T, Diebold J: Molecular

References 1. Schipf A, Mayr D, Kirchner T, Diebold J: Molecular genetic aberrations of ovarian and uterine carcinosarcomas–a CGH and FISH study. Virchows Arch 2008,452(3):259–268.PubMedCrossRef 2. Cantrell LA, Van Le L: Carcinosarcoma of the ovary a review. Obstet Gynecol

Surv 2009,64(10):673–80. quiz 697PubMedCrossRef 3. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010,60(5):277–300.PubMedCrossRef 4. Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, Dusenbery K, Downs LS Jr: Clinical features and outcomes of uterine and ovarian carcinosarcoma. Gynecol Oncol 2006,100(3):561–564.PubMedCrossRef 5. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A: Adjuvant radiotherapy and/or chemotherapy

after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2011,1(1):CD006812.PubMed 6. Garg G, Shah JP, Kumar S, Bryant EPZ004777 CS, Munkarah A, Morris RT: Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer 2010,20(5):888–894.PubMedCrossRef 7. Ripani E, Sacchetti A, Corda D, Alberti S: Human CRT0066101 manufacturer trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998,76(5):671–676.PubMedCrossRef 8. Cubas R, Zhang S, Li M, Chen C, Yao Q: Trop2 expression contributes to tumor pathogenesis by activating Momelotinib cost the ERK MAPK pathway. Mol Cancer 2010, 9:253.PubMedCrossRef 9. Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S, Santin AD: Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 2010,46(5):944–953.PubMedCrossRef 10. Amylase Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-trop-2

monoclonal antibody. Cancer 2011,117(14):3163–3172.PubMedCrossRef 11. Govindan SV, Stein R, Qu Z, Chen S, Andrews P, Ma H, Hansen HJ, Griffiths GL, Horak ID, Goldenberg DM: Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat 2004,84(2):173–182.PubMedCrossRef 12. Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM: Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011,17(10):3157–3169.PubMedCrossRef 13. Chang CH, Gupta P, Michel R, Loo M, Wang Y, Cardillo TM, Goldenberg DM: Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells.

Comments are closed.